Physician profile
Mark J Schnee
NPI 1437153020
$14,056.39
in general payments reported to CMS, 2019-2025
41 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,304 · 2020: $1,363 · 2021: $1,974 · 2022: $2,497 · 2023: $2,466 · 2024: $1,696 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,917.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,840.47 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,646.88 | 2019-2025 | |
| Amgen INC. | $1,330.31 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $1,027.12 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $909.75 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $798.77 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $702.98 | 2021-2024 | Optimizer, Optimizer |
| Amarin Pharma, INC. | $635.22 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $542.17 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $515.03 | 2022-2025 | Verquvo |
| Esperion Therapeutics, INC. | $464.16 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $339.40 | 2019-2024 | Livalo |
| Regeneron Healthcare Solutions, INC. | $310.93 | 2019 | |
| Biosense Webster, INC. | $310.93 | 2023-2024 | Carto 3 |
| Medtronic Vascular, INC. | $302.97 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schnee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.